BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33150503)

  • 1. Co-Delivery of Hispolon and Doxorubicin Liposomes Improves Efficacy Against Melanoma Cells.
    Al Saqr A; Aldawsari MF; Alrbyawi H; Poudel I; Annaji M; Mulabagal V; Ramani MV; Gottumukkala S; Tiwari AK; Dhanasekaran M; Panizzi PR; Arnold RD; Babu RJ
    AAPS PharmSciTech; 2020 Nov; 21(8):304. PubMed ID: 33150503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-delivery of Doxorubicin and Ceramide in a Liposomal Formulation Enhances Cytotoxicity in Murine B16BL6 Melanoma Cell Lines.
    Chen L; Alrbyawi H; Poudel I; Arnold RD; Babu RJ
    AAPS PharmSciTech; 2019 Feb; 20(3):99. PubMed ID: 30719596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hispolon Cyclodextrin Complexes and Their Inclusion in Liposomes for Enhanced Delivery in Melanoma Cell Lines.
    Poudel I; Annaji M; Wibowo FS; Arnold RD; Fasina O; Via B; Rangari V; Peresin MS; Smith F; Dhanasekaran M; Tiwari AK; Babu RJ
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Delivery of Doxorubicin Liposomes for Her-2+ Breast Cancer Treatment.
    Chowdhury N; Chaudhry S; Hall N; Olverson G; Zhang QJ; Mandal T; Dash S; Kundu A
    AAPS PharmSciTech; 2020 Jul; 21(6):202. PubMed ID: 32696338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical study of Doxorubicine-loaded liposomal drug delivery for the treatment of head and neck cancer: Optimization by Box-Behnken statistical design.
    Yang B
    Acta Biochim Pol; 2020 Jun; 67(2):149-155. PubMed ID: 32506868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Specificity and Drug Delivery in Tumors by cRGD-Anchoring Thermosensitive Liposomes.
    Dicheva BM; ten Hagen TL; Seynhaeve AL; Amin M; Eggermont AM; Koning GA
    Pharm Res; 2015 Dec; 32(12):3862-76. PubMed ID: 26202516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies.
    Xiao P; Zhao J; Huang Y; Jin R; Tang Z; Wang P; Song X; Zhu H; Yang Z; Yu N
    Pharm Nanotechnol; 2020; 8(5):391-398. PubMed ID: 32787769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective Remote Loading of Doxorubicin into DPPC/Poloxamer 188 Hybrid Liposome to Retain Thermosensitive Property and the Assessment of Carrier-Based Acute Cytotoxicity for Pulmonary Administration.
    Tagami T; Kubota M; Ozeki T
    J Pharm Sci; 2015 Nov; 104(11):3824-3832. PubMed ID: 26228287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
    Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
    Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
    Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
    Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manufacturing drug co-loaded liposomal formulations targeting breast cancer: Influence of preparative method on liposomes characteristics and in vitro toxicity.
    Gkionis L; Campbell RA; Aojula H; Harris LK; Tirella A
    Int J Pharm; 2020 Nov; 590():119926. PubMed ID: 33010397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of lipid composition on the properties of doxorubicin-loaded liposomes.
    Sakai-Kato K; Nanjo K; Kawanishi T; Okuda H; Goda Y
    Ther Deliv; 2015 Jul; 6(7):785-94. PubMed ID: 26228772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of doxorubicin with harmine-loaded liposomes exerting synergistic antitumor efficacy.
    Lei J; Cong S; Song M; Zhang W; Peng G; Li X; Liu Y
    Drug Dev Ind Pharm; 2018 Apr; 44(4):570-581. PubMed ID: 29260918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced cytotoxicity of doxorubicin encapsulated in liposomes with reconstituted Sendai F-proteins.
    Cho JE; Kim HS; Ahn WS; Park YS
    J Microencapsul; 2001; 18(4):421-31. PubMed ID: 11428672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Membrane-Loaded Doxorubicin Liposomes Based on Ion-Pairing Technology with High Drug Loading and pH-Responsive Property.
    Xu H; Zhang L; Li L; Liu Y; Chao Y; Liu X; Jin Z; Chen Y; Tang X; He H; Kan Q; Cai C
    AAPS PharmSciTech; 2017 Aug; 18(6):2120-2130. PubMed ID: 28028795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-effect liposomes encapsulated with doxorubicin and chlorin e6 augment the therapeutic effect of tumor treatment.
    Peng PC; Hong RL; Tsai YJ; Li PT; Tsai T; Chen CT
    Lasers Surg Med; 2015 Jan; 47(1):77-87. PubMed ID: 25559348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Combined Approach of Short-Chain Sphingolipids and Thermosensitive Liposomes for Improved Drug Delivery to Tumor Cells.
    Haeri A; Pedrosa LR; Ten Hagen TL; Dadashzadeh S; Koning GA
    J Biomed Nanotechnol; 2016 Apr; 12(4):630-44. PubMed ID: 27301190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidating the anti-melanoma effect and mechanisms of Hispolon.
    Al Saqr A; Majrashi M; Alrbyawi H; Govindarajulu M; Fujihashi A; Gottumukkala S; Poudel I; Arnold RD; Babu RJ; Dhanasekaran M
    Life Sci; 2020 Sep; 256():117702. PubMed ID: 32387411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
    Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
    J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
    Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
    Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.